Open an Account
search icon
3
NOTIFICATIONS
Best Algo trading app in India
Bigul

MARKSANS PHARMA LTD. - 524404 - Announcement under Regulation 30 (LODR)-Code of Conduct under SEBI (PIT) Regulations, 2015

 Amendment to the Code of Practices & Procedures for Fair Disclosure of Unpublished Price Sensitive Information Dear Sir, In compliance with the SEBI (Prohibition of insider Trading) (Amendment) Regulations, 2018, the Board of directors of the Company has adopted revised 'Code of Practices and Procedures For Fair Disclosure of Unpublished Price Sensitive Information' effective from April 1, 2019. The said revised code is attached herewith and is also available on the Company's website at www.marksanspharma.com.
02-04-2019
Bigul

Marksans Pharma Ltd - 524404 - Announcement under Regulation 30 (LODR)-Change in Directorate

 Change in Director Pursuant to Regulation 30 of SEBI (Listing Obligation and Disclosure Requirement) Regulation, 2015, please be informed that due to personal reason, Mr. Ajay Shivram Joshi (DIN: 00947684) has resigned as Director of the Company effective from 1st April, 2019.
22-03-2019
Bigul

Company news: Marksans Pharma

 Marksans Pharma on Thursday informed the exchanges that the US FDA has issued Form 483 with eight observations on conclusion of inspection at its Goa
07-03-2019
Bigul

Marksans Pharma Ltd - 524404 - Announcement under Regulation 30 (LODR)-Press Release / Media Release

 US FDA Audit update Dear Sirs, This is to inform that the U.S. FDA has concluded inspection of Company's Goa facility. The inspection of the facility took place between 25th February to 6th March 2019, resulting in a Form 483 with eight observations. None of these observations are considered either critical or repetitive in nature. Company is highly confident of closing these expeditiously and remains commited to global standards of quality & compliance. The site will continue to supply to the US markets all approved ANDA's. This inspection will help Company to received pending ANDA's approval alredy filed by it. This is for your information and records.
07-03-2019
Bigul

Marksans Pharma Ltd - 524404 - Announcement under Regulation 30 (LODR)-Press Release / Media Release

 News Release Enclosed herewith kindly find a News Release dated 8th February, 2019 of the Company. You are requested to note the above in your records.
08-02-2019
Bigul

Marksans Pharma Ltd - 524404 - Unaudited Financial Results For The Quarter Ended 31St December, 2018 And Limited Review Reports Thereon.

 In terms of Regulation 33 of the SEBI (Listing Obligation and Disclosure Requirements) Regulations, 2015, kindly find enclosed herewith Unaudited Financial Results for the quarter ended 31st December, 2018 (both Standalone and Consolidated) approved by the Board of Directors at its meeting held today i.e. 8th February, 2019 along with Limited Review Reports thereon. The meeting commenced at 11:00 a.m. and concluded at 12:15 p.m. In this connection, we hereby certify that the Auditors have given their reports on the Unaudited Financial Results for the quarter ended 31st December, 2018 (both Standalone and Consolidated) with unmodified opinion. You are requested to note the above in your records
08-02-2019
Bigul

Company news: Marksans Pharma

 Marksans Pharma on Tuesday said that UK MHRA has granted marketing authorisation to its wholly-owned subsidiary, Relonchem Ltd, UK, for loratadine 5mg
05-02-2019
Bigul

Marksans Pharma Ltd - 524404 - Announcement under Regulation 30 (LODR)-Press Release / Media Release

 Marksans Pharma Limited announces UK MHRA grant of Marketing Authorisation for Loratadine 5mg/5ml Oral Solution
05-02-2019
Bigul

Marksans Pharma Ltd - 524404 - Clarification

 This has reference to the exchange's e-mail communication dated 1st February, 2019 for clarification on the appointment of Mr. Varddhman Vikramaditya Jain (DIN: 08338573) as a Whole-time Director at its meeting held on 24th January, 2019. In this connection we would like to state that Mr. Varddhman Vikramaditya Jain is not related to any Directors of the Company in any manner.
01-02-2019
Bigul

Marksans Pharma Ltd - 524404 - Closure of Trading Window

 This is to inform you that the Meeting of the Board of Directors of the Company will be held on Friday, 8th February, 2019 at Mumbai, to consider and approve the Unaudited Financial Results of the Company (both Standalone and Consolidated) for the quarter ended 31st December, 2018. Please note that as per the Insider Trading Code of the Company, the Trading Window for dealing in Company's shares will remain closed for the Company's insiders from today i.e. 31st January, 2019 (Commencing from the time of above intimation to the Stock Exchanges) till Forty-Eight hours after the announcement of the Unaudited Financial Results on 8th February, 2019.
31-01-2019
Next Page
Close

Let's Open Free Demat Account